Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01988571 · ClinicalTrials.gov registry record · Phase 2
Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 279
- Enrollment target
NCT01988571 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 279 participants.
The verdict
NCT01988571, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 279 participants
- Enrollment target
Study Summary
The purpose of this research study is to see if Atorvastatin (Lipitor) 40 mg by mouth daily decreases the chance of developing heart problems in individuals receiving adjuvant anthracycline-based chemotherapy for breast cancer of lymphoma.
Interventions
- DRUG Placebo
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2014-02-01 |
| Est. Completion | 2020-09-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01988571
The ClinicalTrials.gov registry entry for NCT01988571 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 279 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01988571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01988571 about?
NCT01988571 is a clinical study titled "Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)". The purpose of this research study is to see if Atorvastatin (Lipitor) 40 mg by mouth daily decreases the chance of developing heart problems in individuals receiving adjuvant anthracycline-based chemotherapy for breast cancer of lymphoma.
What is the current status of trial NCT01988571?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 279 participants. The study started on 2014-02-01. Estimated completion is 2020-09-24.
What interventions are being tested in trial NCT01988571?
The interventions under investigation include: Placebo (DRUG), Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT01988571?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.